pmc logo image
Logo of pubhealthrepJournal URL: http://www.publichealthreports.org/
Journal List > Public Health Rep > v.113(Suppl 1); Jun 1998

Formats:
Public Health Rep. 1998 June; 113(Suppl 1): 67–74.
PMCID: PMC1307728
Copyright notice
Syringe exchange programs: lowering the transmission of syringe-borne diseases and beyond.
R Heimer
Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT 06520-8034, USA. robert.heimer@yale.edu
Small right arrow pointing to: This article has been cited by other articles in PMC.
Abstract
OBJECTIVE: This chapter attempts to describe the factors influencing the transmission of syringe-born viruses, to review the effects of syringe exchange programs (SEPs) in terms of these factors, and to explore the gamut of health-promoting activities of SEPs. RESULTS: The chapter is divided into six sections: biological factors in syringe-borne viral transmission, behavior and viral transmission, quantifying viral transmission, preventing viral transmission, impediments to preventing viral transmission, and research for preventing viral transmission. Understanding how biological and behavioral factors influence transmission of human immunodeficiency virus (HIV) and hepatitis builds a framework to investigate the epidemiology and the impact of SEPs on disease transmission. Even under circumstances in which these programs do not appear to be effective, understanding the implications of the biological and behavioral factors can contribute to our understanding of program benefits and limitations. Furthermore, program benefits may not be restricted to direct effects on disease transmission. Many programs offer services to drug injectors that include risk reduction training, facilitated entry into substance abuse treatment, and medical care. CONCLUSIONS: SEPs can reduce the transmission of syringe-borne viruses without increasing illicit drug use. However, lack of resources, acceptance, and consequently, protection of many of those at risk when they are most vulnerable have hampered program effectiveness. New studies need to be designed to explicate the full measure of program benefit within covered communities and identify the means by which SEPs can expand benefit to individuals at greatest risk.
Full text
Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.5M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
 
icon of scanned page 67
67
icon of scanned page 68
68
icon of scanned page 69
69
icon of scanned page 70
70
icon of scanned page 71
71
icon of scanned page 72
72
icon of scanned page 73
73
icon of scanned page 74
74
 
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
  • Des Jarlais DC, Hagan H, Friedman SR, Friedmann P, Goldberg D, Frischer M, Green S, Tunving K, Ljungberg B, Wodak A, et al. Maintaining low HIV seroprevalence in populations of injecting drug users. JAMA. 1995 Oct 18;274(15):1226–1231. [PubMed]
  • Chaisson RE, Moss AR, Onishi R, Osmond D, Carlson JR. Human immunodeficiency virus infection in heterosexual intravenous drug users in San Francisco. Am J Public Health. 1987 Feb;77(2):169–172. [PubMed]
  • Schoenbaum EE, Hartel D, Selwyn PA, Klein RS, Davenny K, Rogers M, Feiner C, Friedland G. Risk factors for human immunodeficiency virus infection in intravenous drug users. N Engl J Med. 1989 Sep 28;321(13):874–879. [PubMed]
  • Choopanya K, Vanichseni S, Des Jarlais DC, Plangsringarm K, Sonchai W, Carballo M, Friedmann P, Friedman SR. Risk factors and HIV seropositivity among injecting drug users in Bangkok. AIDS. 1991 Dec;5(12):1509–1513. [PubMed]
  • Donahue JG, Nelson KE, Muñoz A, Vlahov D, Rennie LL, Taylor EL, Saah AJ, Cohn S, Odaka NJ, Farzadegan H. Antibody to hepatitis C virus among cardiac surgery patients, homosexual men, and intravenous drug users in Baltimore, Maryland. Am J Epidemiol. 1991 Nov 15;134(10):1206–1211. [PubMed]
  • Zeldis JB, Jain S, Kuramoto IK, Richards C, Sazama K, Samuels S, Holland PV, Flynn N. Seroepidemiology of viral infections among intravenous drug users in northern California. West J Med. 1992 Jan;156(1):30–35. [PubMed]
  • Levine OS, Vlahov D, Nelson KE. Epidemiology of hepatitis B virus infections among injecting drug users: seroprevalence, risk factors, and viral interactions. Epidemiol Rev. 1994;16(2):418–436. [PubMed]
  • Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989 Apr 21;244(4902):359–362. [PubMed]
  • Short LJ, Bell DM. Risk of occupational infection with blood-borne pathogens in operating and delivery room settings. Am J Infect Control. 1993 Dec;21(6):343–350. [PubMed]
  • Kaplan EH, Heimer R. A model-based estimate of HIV infectivity via needle sharing. J Acquir Immune Defic Syndr. 1992;5(11):1116–1118. [PubMed]
  • Resnick L, Veren K, Salahuddin SZ, Tondreau S, Markham PD. Stability and inactivation of HTLV-III/LAV under clinical and laboratory environments. JAMA. 1986 Apr 11;255(14):1887–1891. [PubMed]
  • Moudgil T, Daar ES. Infectious decay of human immunodeficiency virus type 1 in plasma. J Infect Dis. 1993 Jan;167(1):210–212. [PubMed]
  • Shapshak P, McCoy CB, Shah SM, Page JB, Rivers JE, Weatherby NL, Chitwood DD, Mash DC. Preliminary laboratory studies of inactivation of HIV-1 in needles and syringes containing infected blood using undiluted household bleach. J Acquir Immune Defic Syndr. 1994 Jul;7(7):754–759. [PubMed]
  • Gleghorn AA, Doherty MC, Vlahov D, Celentano DD, Jones TS. Inadequate bleach contact times during syringe cleaning among injection drug users. J Acquir Immune Defic Syndr. 1994 Jul;7(7):767–772. [PubMed]
  • Titus S, Marmor M, Des Jarlais D, Kim M, Wolfe H, Beatrice S. Bleach use and HIV seroconversion among New York City injection drug users. J Acquir Immune Defic Syndr. 1994 Jul;7(7):700–704. [PubMed]
  • Vlahov D, Astemborski J, Solomon L, Nelson KE. Field effectiveness of needle disinfection among injecting drug users. J Acquir Immune Defic Syndr. 1994 Jul;7(7):760–766. [PubMed]
  • D'Aquila RT, Peterson LR, Williams AB, Williams AE. Race/ethnicity as a risk factor for HIV-1 infection among Connecticut intravenous drug users. J Acquir Immune Defic Syndr. 1989;2(5):503–513. [PubMed]
  • Risk behaviors for HIV transmission among intravenous-drug users not in drug treatment--United States, 1987-1989. MMWR Morb Mortal Wkly Rep. 1990 Apr 27;39(16):273–276. [PubMed]
  • Robles RR, Colón HM, Sahai H, Matos TD, Marrero CA, Reyes JC. Behavioral risk factors and human immunodeficiency virus (HIV) prevalence among intravenous drug users in Puerto Rico. Am J Epidemiol. 1992 Mar 1;135(5):531–540. [PubMed]
  • Moss AR, Vranizan K, Gorter R, Bacchetti P, Watters J, Osmond D. HIV seroconversion in intravenous drug users in San Francisco, 1985-1990. AIDS. 1994 Feb;8(2):223–231. [PubMed]
  • Chitwood DD, Griffin DK, Comerford M, Page JB, Trapido EJ, Lai S, McCoy CB. Risk factors for HIV-1 seroconversion among injection drug users: a case-control study. Am J Public Health. 1995 Nov;85(11):1538–1542. [PubMed]
  • Groseclose SL, Weinstein B, Jones TS, Valleroy LA, Fehrs LJ, Kassler WJ. Impact of increased legal access to needles and syringes on practices of injecting-drug users and police officers--Connecticut, 1992-1993. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Sep 1;10(1):82–89. [PubMed]
  • Vlahov D, Polk BF. Perspectives on infection with HIV-1 among intravenous drug users. Psychopharmacol Bull. 1988;24(3):325–329. [PubMed]
  • Kaplan EH. Needles that kill: modeling human immunodeficiency virus transmission via shared drug injection equipment in shooting galleries. Rev Infect Dis. 1989 Mar–Apr;11(2):289–298. [PubMed]
  • Vlahov D, Junge B. The role of needle exchange programs in HIV prevention. Public Health Rep. 1998 Jun;113 Suppl 1:75–80. [PubMed]
  • Kaplan EH, Heimer R. A circulation theory of needle exchange. AIDS. 1994 May;8(5):567–574. [PubMed]
  • Kaplan EH. A method for evaluating needle exchange programmes. Stat Med. 13(19-20):2179–2187. [PubMed]
  • Des Jarlais DC, Marmor M, Paone D, Titus S, Shi Q, Perlis T, Jose B, Friedman SR. HIV incidence among injecting drug users in New York City syringe-exchange programmes. Lancet. 1996 Oct 12;348(9033):987–991. [PubMed]
  • Hagan H, Jarlais DC, Friedman SR, Purchase D, Alter MJ. Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma syringe exchange program. Am J Public Health. 1995 Nov;85(11):1531–1537. [PubMed]
  • Heimer R, Khoshnood K, Jariwala-Freeman B, Duncan B, Harima Y. Hepatitis in used syringes: the limits of sensitivity of techniques to detect hepatitis B virus (HBV) DNA, hepatitis C virus (HCV) RNA, and antibodies to HBV core and HCV antigens. J Infect Dis. 1996 Apr;173(4):997–1000. [PubMed]
  • Heimer R, Kaplan EH, Khoshnood K, Jariwala B, Cadman EC. Needle exchange decreases the prevalence of HIV-1 proviral DNA in returned syringes in New Haven, Connecticut. Am J Med. 1993 Aug;95(2):214–220. [PubMed]
  • Lurie P, Drucker E. An opportunity lost: HIV infections associated with lack of a national needle-exchange programme in the USA. Lancet. 1997 Mar 1;349(9052):604–608. [PubMed]
  • Strathdee SA, Patrick DM, Currie SL, Cornelisse PG, Rekart ML, Montaner JS, Schechter MT, O'Shaughnessy MV. Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS. 1997 Jul;11(8):F59–F65. [PubMed]
  • Bruneau J, Lamothe F, Franco E, Lachance N, Désy M, Soto J, Vincelette J. High rates of HIV infection among injection drug users participating in needle exchange programs in Montreal: results of a cohort study. Am J Epidemiol. 1997 Dec 15;146(12):994–1002. [PubMed]
  • Lurie P. Invited commentary: le mystère de Montréal. Am J Epidemiol. 1997 Dec 15;146(12):1003–1010. [PubMed]
  • Update: syringe-exchange programs--United States, 1996. MMWR Morb Mortal Wkly Rep. 1997 Jun 20;46(24):565–568. [PubMed]
  • Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health. 1996 May;86(5):655–661. [PubMed]
  • Heimer R, Bluthenthal RN, Singer M, Khoshnood K. Structural impediments to operational syringe-exchange programs. AIDS Public Policy J. 1996 Winter;11(4):169–184. [PubMed]
  • Perlman DC, Perkins MP, Solomon N, Kochems L, Des Jarlais DC, Paone D. Tuberculosis screening at a syringe exchange program. Am J Public Health. 1997 May;87(5):862–863. [PubMed]
  • Burris S, Finucane D, Gallagher H, Grace J. The legal strategies used in operating syringe exchange programs in the United States. Am J Public Health. 1996 Aug;86(8):1161–1166. [PubMed]
  • Gostin LO, Lazzarini Z, Jones TS, Flaherty K. Prevention of HIV/AIDS and other blood-borne diseases among injection drug users. A national survey on the regulation of syringes and needles. JAMA. 1997 Jan 1;277(1):53–62. [PubMed]
Articles from Public Health Reports are provided here courtesy of
Association of Schools of Public Health

PubMed articles by these authors

Links